- Home
- IVP vs GNPX Comparison
IVP vs GNPX Comparison
Compare IVP & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- GNPX
- Stock Information
- Founded
- IVP 2020
- GNPX 2009
- Country
- IVP United States
- GNPX United States
- Employees
- IVP N/A
- GNPX N/A
- Industry
- IVP Diversified Commercial Services
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- GNPX Health Care
- Exchange
- IVP Nasdaq
- GNPX Nasdaq
- Market Cap
- IVP 7.8M
- GNPX 7.0M
- IPO Year
- IVP 2023
- GNPX 2018
- Fundamental
- Price
- IVP $1.62
- GNPX $0.25
- Analyst Decision
- IVP
- GNPX Strong Buy
- Analyst Count
- IVP 0
- GNPX 1
- Target Price
- IVP N/A
- GNPX $10.00
- AVG Volume (30 Days)
- IVP 48.6K
- GNPX 2.9M
- Earning Date
- IVP 05-27-2025
- GNPX 05-12-2025
- Dividend Yield
- IVP N/A
- GNPX N/A
- EPS Growth
- IVP N/A
- GNPX N/A
- EPS
- IVP N/A
- GNPX N/A
- Revenue
- IVP $15,399,751.00
- GNPX N/A
- Revenue This Year
- IVP N/A
- GNPX N/A
- Revenue Next Year
- IVP N/A
- GNPX N/A
- P/E Ratio
- IVP N/A
- GNPX N/A
- Revenue Growth
- IVP N/A
- GNPX N/A
- 52 Week Low
- IVP $1.26
- GNPX $0.22
- 52 Week High
- IVP $401.50
- GNPX $4.09
- Technical
- Relative Strength Index (RSI)
- IVP 52.40
- GNPX 43.11
- Support Level
- IVP $1.47
- GNPX $0.22
- Resistance Level
- IVP $2.06
- GNPX $0.36
- Average True Range (ATR)
- IVP 0.18
- GNPX 0.03
- MACD
- IVP 0.03
- GNPX -0.00
- Stochastic Oscillator
- IVP 37.05
- GNPX 22.05
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.